董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ali Behbahani | 男 | Independent Director | 49 | 10.55万美元 | 未持股 | 2025-09-10 |
| Adrian Rawcliffe | 男 | Director and Chief Executive Officer | 53 | 153.58万美元 | 未持股 | 2025-09-10 |
| John P. Furey | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-10 |
| Priti Hegde | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-10 |
| Kristen M. Hege | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-10 |
| Garry E. Menzel | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-10 |
| Andrew R. Allen | -- | Independent Director | -- | 未披露 | 未持股 | 2025-09-10 |
| David M. Mott | 男 | Chairman of the Board | 60 | 14.45万美元 | 未持股 | 2025-09-10 |
| Lawrence M. Alleva | 男 | Independent Director | 76 | 11.64万美元 | 未持股 | 2025-09-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adrian Rawcliffe | 男 | Director and Chief Executive Officer | 53 | 153.58万美元 | 未持股 | 2025-09-10 |
| William Bertrand | 男 | Chief Operating Officer | 60 | 未披露 | 未持股 | 2025-09-10 |
| Joanna Brewer | -- | Chief Scientific Officer | -- | 未披露 | 未持股 | 2025-09-10 |
| Christopher Hill | 男 | Chief Financial Officer | 45 | 未披露 | 未持股 | 2025-09-10 |
董事简历
中英对照 | 中文 | 英文- Ali Behbahani
-
Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University. - Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
- Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University.
- Adrian Rawcliffe
-
Adrian Rawcliffe自2017年2月起担任董事。Rawcliffe先生目前担任Adaptimmune治疗有限公司的首席财务官，自2015年以来一直在该公司工作。在加入Adaptimmune之前，罗克里夫曾在GlaxoSmithKline plc担任多个职位，包括2011年至2015年担任高级副总裁金融、北美制药和全球特许经营商；2006年至2011年担任高级副总裁，全球业务开发和研发金融；Vice President，2003年至2005年，负责全球业务发展交易和风险投资；2001年至2003年，负责Vice President的交易结构。从2005年到2006年，Rawcliffe先生担任SR One Ltd.的总裁兼管理合伙人。Rawcliffe先生从1993年到1997年在Coopers&Lybrand（现在的普华永道会计师事务所）担任主管开始他的职业生涯。Rawcliffe先生获得学士学位。获英国达勒姆大学自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计培训。
Adrian Rawcliffe,has served as a director since February 2017. Since September 2019, Mr. Rawcliffe has served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc., a publicly traded clinical-stage biopharmaceutical company. Mr. Rawcliffe also serves on the board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune Therapeutics plc. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW). - Adrian Rawcliffe自2017年2月起担任董事。Rawcliffe先生目前担任Adaptimmune治疗有限公司的首席财务官，自2015年以来一直在该公司工作。在加入Adaptimmune之前，罗克里夫曾在GlaxoSmithKline plc担任多个职位，包括2011年至2015年担任高级副总裁金融、北美制药和全球特许经营商；2006年至2011年担任高级副总裁，全球业务开发和研发金融；Vice President，2003年至2005年，负责全球业务发展交易和风险投资；2001年至2003年，负责Vice President的交易结构。从2005年到2006年，Rawcliffe先生担任SR One Ltd.的总裁兼管理合伙人。Rawcliffe先生从1993年到1997年在Coopers&Lybrand（现在的普华永道会计师事务所）担任主管开始他的职业生涯。Rawcliffe先生获得学士学位。获英国达勒姆大学自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计培训。
- Adrian Rawcliffe,has served as a director since February 2017. Since September 2019, Mr. Rawcliffe has served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc., a publicly traded clinical-stage biopharmaceutical company. Mr. Rawcliffe also serves on the board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune Therapeutics plc. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW).
- John P. Furey
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Priti Hegde
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kristen M. Hege
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Garry E. Menzel
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Andrew R. Allen
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- David M. Mott
-
David M. Mott，自2016年1月起担任董事会成员。Mott先生自2020年2月起通过Mott Family Capital成为私人投资者，此前曾于2008年9月至2020年2月期间担任风险投资公司New Enterprise Associates，Inc.的普通合伙人，并与其关联公司一起持有超过5种有表决权的证券。从1992年到2008年，Mott先生曾在MedImmune，Inc.（MedImmune）工作。在此期间，Mott先生还在2007年6月至2008年7月期间担任阿斯利康执行副总裁，此前阿斯利康于2007年6月收购了MedImmune。Mott先生曾在多家上市公司的董事会任职，包括一家上市生物制药公司Epizyme, Inc.，自2009年以来，一家上市的专业化生物制药公司Ardelyx, Inc.，自2009年以来，一家上市的临床阶段生物制药公司Adaptimmune治疗 PLC，自2014年9月以来，一家上市的生命科学公司Mersana Therapeutics, Inc.，自2012年7月以来，一家上市的晚期生物技术公司Novavax, Inc.，自2020年6月以来，曾在生物制药公司Tiburio Therapeutics，Inc.的董事会任职。Mott先生还在几家私营生物制药公司的董事会任职。Mott先生在达特茅斯学院获得经济学和政府学士学位。
David M. Mott has served as a member of board of directors since January 2016. Mr. Mott has been a private investor through Mott Family Capital since February 2020 and previously served as a General Partner at New Enterprise Associates, Inc., a venture capital firm and, with its affiliates, a holder of more than 5 of voting securities, from September 2008 to February 2020 where he led the healthcare investing practice. From 1992 until 2008 Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca plc, or AstraZeneca, a public global, science-led biopharmaceutical company, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZeneca's acquisition of MedImmune in June 2007. Mr. Mott has served on the board of directors of several public companies, including Epizyme, Inc., a public biopharmaceutical company, since 2009 Ardelyx, Inc., a public specialized biopharmaceutical company, since 2009 Adaptimmune Therapeutics plc, a public clinical-stage biopharmaceutical company, since September 2014 Mersana Therapeutics, Inc., a public life sciences company, since July 2012 and Novavax, Inc., a public late-stage biotechnology company, since June 2020 and previously served on the board of Tiburio Therapeutics, Inc., a biopharmaceutical company, from December 2018 to February 2020 Nightstar Therapeutics plc, a public gene therapy company that was acquired by Biogen in June 2019 from November 2015 to June 2019 Clementia Pharmaceuticals, Inc., a clinical-stage company, from June 2015 to February 2018 and Tesaro, Inc., an oncology-focused company, from May 2010 to January 2019. Mr. Mott also serves on the boards of several private biopharmaceutical companies. Mr. Mott received his B.A. in economics and government from Dartmouth College. - David M. Mott，自2016年1月起担任董事会成员。Mott先生自2020年2月起通过Mott Family Capital成为私人投资者，此前曾于2008年9月至2020年2月期间担任风险投资公司New Enterprise Associates，Inc.的普通合伙人，并与其关联公司一起持有超过5种有表决权的证券。从1992年到2008年，Mott先生曾在MedImmune，Inc.（MedImmune）工作。在此期间，Mott先生还在2007年6月至2008年7月期间担任阿斯利康执行副总裁，此前阿斯利康于2007年6月收购了MedImmune。Mott先生曾在多家上市公司的董事会任职，包括一家上市生物制药公司Epizyme, Inc.，自2009年以来，一家上市的专业化生物制药公司Ardelyx, Inc.，自2009年以来，一家上市的临床阶段生物制药公司Adaptimmune治疗 PLC，自2014年9月以来，一家上市的生命科学公司Mersana Therapeutics, Inc.，自2012年7月以来，一家上市的晚期生物技术公司Novavax, Inc.，自2020年6月以来，曾在生物制药公司Tiburio Therapeutics，Inc.的董事会任职。Mott先生还在几家私营生物制药公司的董事会任职。Mott先生在达特茅斯学院获得经济学和政府学士学位。
- David M. Mott has served as a member of board of directors since January 2016. Mr. Mott has been a private investor through Mott Family Capital since February 2020 and previously served as a General Partner at New Enterprise Associates, Inc., a venture capital firm and, with its affiliates, a holder of more than 5 of voting securities, from September 2008 to February 2020 where he led the healthcare investing practice. From 1992 until 2008 Mr. Mott worked at MedImmune, Inc., or MedImmune, a biotechnology company and subsidiary of AstraZeneca plc, or AstraZeneca, a public global, science-led biopharmaceutical company, and served in numerous roles during his tenure, including most recently as Chief Executive Officer from October 2000 to July 2008. During that time, Mr. Mott also served as Executive Vice President of AstraZeneca from June 2007 to July 2008 following AstraZeneca's acquisition of MedImmune in June 2007. Mr. Mott has served on the board of directors of several public companies, including Epizyme, Inc., a public biopharmaceutical company, since 2009 Ardelyx, Inc., a public specialized biopharmaceutical company, since 2009 Adaptimmune Therapeutics plc, a public clinical-stage biopharmaceutical company, since September 2014 Mersana Therapeutics, Inc., a public life sciences company, since July 2012 and Novavax, Inc., a public late-stage biotechnology company, since June 2020 and previously served on the board of Tiburio Therapeutics, Inc., a biopharmaceutical company, from December 2018 to February 2020 Nightstar Therapeutics plc, a public gene therapy company that was acquired by Biogen in June 2019 from November 2015 to June 2019 Clementia Pharmaceuticals, Inc., a clinical-stage company, from June 2015 to February 2018 and Tesaro, Inc., an oncology-focused company, from May 2010 to January 2019. Mr. Mott also serves on the boards of several private biopharmaceutical companies. Mr. Mott received his B.A. in economics and government from Dartmouth College.
- Lawrence M. Alleva
-
Lawrence M. Alleva，是一名非在职注册会计师，职业生涯效力于普华永道会计师事务所（PWC），其中合伙人时间为28年，从1971年到2010年退休。在普华永道，他为从《财富》500强和跨国公司到追求首次公开募股的快速增长公司的客户提供服务。Alleva先生还在普华永道道德与合规小组担任高级国家领导职务，负责管理最佳实践程序、内部控制和监测活动的设计和实施，包括普华永道对上市公司会计监督委员会发布的检查报告的回应。Alleva先生目前担任Adaptimmune治疗 PLC、Tesaro，Inc.和Mersana Therapeutics Inc.的董事和审计委员会主席，此前曾在Mirna Therapeutics，Inc.和GlobalLogic，Inc.担任类似职务。他已担任伊萨卡学院的受托人超过20年，其中包括担任副主席一职长达十年。
Lawrence M. Alleva,is a Certified Public Accountant inactive and spent his professional career with PricewaterhouseCoopers LLP (PwC), including 28 years as a partner, from 1971 until his retirement in 2010. At PwC he served clients ranging from Fortune 500 and multi-national companies to rapid-growth companies pursuing initial public offerings. Mr. Alleva also served in a senior national leadership role for PwC's Ethics and Compliance Group to manage the design and implementation of best practice procedures, internal controls and monitoring activities, including PwC's response to inspection reports issued by the Public Company Accounting Oversight Board. Mr. Alleva currently serves as a director and chair of the audit committees of Adaptimmune Therapeutics PLC, Tesaro, Inc. and Mersana Therapeutics Inc., and, previously served in a similar capacity for Mirna Therapeutics, Inc. and GlobalLogic, Inc. He has served as a trustee of Ithaca College for over 20 years, including in the vice chair role for ten years. - Lawrence M. Alleva，是一名非在职注册会计师，职业生涯效力于普华永道会计师事务所（PWC），其中合伙人时间为28年，从1971年到2010年退休。在普华永道，他为从《财富》500强和跨国公司到追求首次公开募股的快速增长公司的客户提供服务。Alleva先生还在普华永道道德与合规小组担任高级国家领导职务，负责管理最佳实践程序、内部控制和监测活动的设计和实施，包括普华永道对上市公司会计监督委员会发布的检查报告的回应。Alleva先生目前担任Adaptimmune治疗 PLC、Tesaro，Inc.和Mersana Therapeutics Inc.的董事和审计委员会主席，此前曾在Mirna Therapeutics，Inc.和GlobalLogic，Inc.担任类似职务。他已担任伊萨卡学院的受托人超过20年，其中包括担任副主席一职长达十年。
- Lawrence M. Alleva,is a Certified Public Accountant inactive and spent his professional career with PricewaterhouseCoopers LLP (PwC), including 28 years as a partner, from 1971 until his retirement in 2010. At PwC he served clients ranging from Fortune 500 and multi-national companies to rapid-growth companies pursuing initial public offerings. Mr. Alleva also served in a senior national leadership role for PwC's Ethics and Compliance Group to manage the design and implementation of best practice procedures, internal controls and monitoring activities, including PwC's response to inspection reports issued by the Public Company Accounting Oversight Board. Mr. Alleva currently serves as a director and chair of the audit committees of Adaptimmune Therapeutics PLC, Tesaro, Inc. and Mersana Therapeutics Inc., and, previously served in a similar capacity for Mirna Therapeutics, Inc. and GlobalLogic, Inc. He has served as a trustee of Ithaca College for over 20 years, including in the vice chair role for ten years.
高管简历
中英对照 | 中文 | 英文- Adrian Rawcliffe
Adrian Rawcliffe自2017年2月起担任董事。Rawcliffe先生目前担任Adaptimmune治疗有限公司的首席财务官，自2015年以来一直在该公司工作。在加入Adaptimmune之前，罗克里夫曾在GlaxoSmithKline plc担任多个职位，包括2011年至2015年担任高级副总裁金融、北美制药和全球特许经营商；2006年至2011年担任高级副总裁，全球业务开发和研发金融；Vice President，2003年至2005年，负责全球业务发展交易和风险投资；2001年至2003年，负责Vice President的交易结构。从2005年到2006年，Rawcliffe先生担任SR One Ltd.的总裁兼管理合伙人。Rawcliffe先生从1993年到1997年在Coopers&Lybrand（现在的普华永道会计师事务所）担任主管开始他的职业生涯。Rawcliffe先生获得学士学位。获英国达勒姆大学自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计培训。
Adrian Rawcliffe,has served as a director since February 2017. Since September 2019, Mr. Rawcliffe has served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc., a publicly traded clinical-stage biopharmaceutical company. Mr. Rawcliffe also serves on the board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune Therapeutics plc. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW).- Adrian Rawcliffe自2017年2月起担任董事。Rawcliffe先生目前担任Adaptimmune治疗有限公司的首席财务官，自2015年以来一直在该公司工作。在加入Adaptimmune之前，罗克里夫曾在GlaxoSmithKline plc担任多个职位，包括2011年至2015年担任高级副总裁金融、北美制药和全球特许经营商；2006年至2011年担任高级副总裁，全球业务开发和研发金融；Vice President，2003年至2005年，负责全球业务发展交易和风险投资；2001年至2003年，负责Vice President的交易结构。从2005年到2006年，Rawcliffe先生担任SR One Ltd.的总裁兼管理合伙人。Rawcliffe先生从1993年到1997年在Coopers&Lybrand（现在的普华永道会计师事务所）担任主管开始他的职业生涯。Rawcliffe先生获得学士学位。获英国达勒姆大学自然科学学士学位。Rawcliffe先生还通过英格兰和威尔士特许会计师协会（ICAEW）接受了特许会计培训。
- Adrian Rawcliffe,has served as a director since February 2017. Since September 2019, Mr. Rawcliffe has served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc., a publicly traded clinical-stage biopharmaceutical company. Mr. Rawcliffe also serves on the board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune Therapeutics plc. From 2015 to September 2019, he served as Adaptimmune's Chief Financial Officer. Prior to joining Adaptimmune, Mr. Rawcliffe served in various roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&D Finance from 2006 to 2011; Vice President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr. Rawcliffe served as the President and Managing Partner of SR One Ltd. Mr. Rawcliffe began his career as a supervisor at Coopers & Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr. Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr. Rawcliffe also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW).
- William Bertrand
William Bertrand，Bertrand先生自2017年3月起担任我们的首席运营官，负责一系列运营职能，包括合规，风险管理，人力资源和法律/IP。他还曾担任Salix Pharmaceuticals的执行Vice President、总法律顾问，以及高级副总裁，代理首席运营官and General Counsel，在那里他继续担任总经理，以帮助完成公司于2015年4月被Valeant Pharmaceuticals公司以140亿美元收购的整合。他目前是Ardelyx，Inc.的董事会成员。纳斯达克股票代码:ARDX，曾担任包括Trustwave公司和Inotek Pharmaceuticals公司在内的多家私人公司的董事会成员。Bertrand先生在威斯康星大学（University of Wisconsin）获得法学博士学位，在韦恩州立大学（Wayne State University）获得生物学学士学位。
William Bertrand,Mr. Bertrand has served as Chief Operating Officer since March 2017 and is responsible for a range of operational functions including compliance, risk management, human resources and legal/IP. He has also formerly served as Executive Vice President, General Counsel for Infinity Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company's $14 billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx, Inc. NASDAQ: ARDX and has served as a member of the board of directors of several private companies including Trustwave and Inotek Pharmaceuticals. Mr. Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University.- William Bertrand，Bertrand先生自2017年3月起担任我们的首席运营官，负责一系列运营职能，包括合规，风险管理，人力资源和法律/IP。他还曾担任Salix Pharmaceuticals的执行Vice President、总法律顾问，以及高级副总裁，代理首席运营官and General Counsel，在那里他继续担任总经理，以帮助完成公司于2015年4月被Valeant Pharmaceuticals公司以140亿美元收购的整合。他目前是Ardelyx，Inc.的董事会成员。纳斯达克股票代码:ARDX，曾担任包括Trustwave公司和Inotek Pharmaceuticals公司在内的多家私人公司的董事会成员。Bertrand先生在威斯康星大学（University of Wisconsin）获得法学博士学位，在韦恩州立大学（Wayne State University）获得生物学学士学位。
- William Bertrand,Mr. Bertrand has served as Chief Operating Officer since March 2017 and is responsible for a range of operational functions including compliance, risk management, human resources and legal/IP. He has also formerly served as Executive Vice President, General Counsel for Infinity Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company's $14 billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx, Inc. NASDAQ: ARDX and has served as a member of the board of directors of several private companies including Trustwave and Inotek Pharmaceuticals. Mr. Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University.
- Joanna Brewer
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Christopher Hill
Christopher Hill，在公立和私立生命科学公司担任首席财务官和首席运营官职务。自2021年9月起，他担任Istesso Limited的首席财务官和首席运营官（“COO”），Istesso Limited是一家私营药物开发公司，拥有临床前至IIB期资产，开发自身免疫和纤维化疾病的新疗法。他将于2025年9月9日辞去Istesso Limited的首席财务官和首席运营官职务。此前，Hill先生于2020年4月至2021年9月期间担任私营细胞治疗公司Ixaka Limited的兼职首席财务官，并于2019年3月至2021年9月期间担任OXSonics Therapeutics Limited的财务总监，该公司是一家私营临床阶段疗法公司，致力于开发针对实体瘤癌症的改进给药解决方案。他此前还曾在私营家具制造商Luke Hughes and Company Limited担任兼职首席财务官，从2018年3月到2019年6月，负责监督公司重组。Hill先生于2013年10月至2018年1月期间担任Oxford Pharmascience Group Plc的首席财务官和董事会成员，该公司以前是一家在AIM上市的专注于胃安全NSAIDs的药物开发公司。Hill先生负责集团内的财务、法律和人力资源职能以及AIM和其他监管报告。在他任职期间，该公司经历了一次分拆，其业务被分拆为Abaco Capital（AIM：ABAA）和私营公司Oxford Pharmascience Limited。他之前担任的其他职务包括2010年7月至2013年10月在Ora Capital Partners Limited担任集团财务总监，该公司此前是一家在AIM上市的投资工具，并于2005年6月至2010年6月在国际审计、专业服务和咨询公司Grant Thornton UK LLP担任高级审计。他目前担任私营公司、Connexion Therapeutics Group Limited和CJH Financial Limited的董事。Hill先生是一名特许会计师，拥有利兹城市大学经济学和公共政策学士学位。
Christopher Hill,serving in chief financial officer and chief operating officer roles in public and private life science companies. Since September 2021, he has served as Chief Financial Officer and Chief Operating Officer ("COO") of Istesso Limited, a private drug development company with pre-clinical to phase IIb assets developing new therapies in auto-immune and fibrotic diseases. He will step down from his CFO and COO roles with Istesso Limited on September 9, 2025. Previously, Mr. Hill served as part-time Chief Financial Officer of Ixaka Limited, a private cell therapy company, from April 2020 through September 2021 and as Finance Director of OxSonics Therapeutics Limited, a private clinical stage therapeutics company developing improved drug delivery solutions to solid tumour cancers, from March 2019 through September 2021. He also previously served as part-time Chief Financial Officer of Luke Hughes and Company Limited, a private furniture manufacturer, from March 2018 through June 2019 where he oversaw a corporate restructure. Mr. Hill served as Chief Financial Officer and a member of the Board of Directors of Oxford Pharmascience Group Plc, formerly a publicly listed drug development company on AIM focused on gastro-safe NSAIDs, from October 2013 through January 2018. Mr. Hill had responsibility for the financial, legal and HR functions within the group and for AIM and other regulatory reporting. During his tenure, the company underwent a demerger, and its operations were spun out into Abaco Capital (AIM: ABAA) and private company, Oxford Pharmascience Limited. His other prior roles include serving as Group Financial Controller at Ora Capital Partners Limited, previously an AIM-listed investment vehicle, from July 2010 through October 2013, and as Audit Senior at international audit, professional services and consulting firm, Grant Thornton UK LLP, from June 2005 to June 2010. He currently serves as a director of private companies, Connexion Therapeutics Group Limited and CJH Financial Limited. Mr. Hill is a chartered accountant and holds a B.A. degree in Economics and Public Policy from Leeds Metropolitan University.- Christopher Hill，在公立和私立生命科学公司担任首席财务官和首席运营官职务。自2021年9月起，他担任Istesso Limited的首席财务官和首席运营官（“COO”），Istesso Limited是一家私营药物开发公司，拥有临床前至IIB期资产，开发自身免疫和纤维化疾病的新疗法。他将于2025年9月9日辞去Istesso Limited的首席财务官和首席运营官职务。此前，Hill先生于2020年4月至2021年9月期间担任私营细胞治疗公司Ixaka Limited的兼职首席财务官，并于2019年3月至2021年9月期间担任OXSonics Therapeutics Limited的财务总监，该公司是一家私营临床阶段疗法公司，致力于开发针对实体瘤癌症的改进给药解决方案。他此前还曾在私营家具制造商Luke Hughes and Company Limited担任兼职首席财务官，从2018年3月到2019年6月，负责监督公司重组。Hill先生于2013年10月至2018年1月期间担任Oxford Pharmascience Group Plc的首席财务官和董事会成员，该公司以前是一家在AIM上市的专注于胃安全NSAIDs的药物开发公司。Hill先生负责集团内的财务、法律和人力资源职能以及AIM和其他监管报告。在他任职期间，该公司经历了一次分拆，其业务被分拆为Abaco Capital（AIM：ABAA）和私营公司Oxford Pharmascience Limited。他之前担任的其他职务包括2010年7月至2013年10月在Ora Capital Partners Limited担任集团财务总监，该公司此前是一家在AIM上市的投资工具，并于2005年6月至2010年6月在国际审计、专业服务和咨询公司Grant Thornton UK LLP担任高级审计。他目前担任私营公司、Connexion Therapeutics Group Limited和CJH Financial Limited的董事。Hill先生是一名特许会计师，拥有利兹城市大学经济学和公共政策学士学位。
- Christopher Hill,serving in chief financial officer and chief operating officer roles in public and private life science companies. Since September 2021, he has served as Chief Financial Officer and Chief Operating Officer ("COO") of Istesso Limited, a private drug development company with pre-clinical to phase IIb assets developing new therapies in auto-immune and fibrotic diseases. He will step down from his CFO and COO roles with Istesso Limited on September 9, 2025. Previously, Mr. Hill served as part-time Chief Financial Officer of Ixaka Limited, a private cell therapy company, from April 2020 through September 2021 and as Finance Director of OxSonics Therapeutics Limited, a private clinical stage therapeutics company developing improved drug delivery solutions to solid tumour cancers, from March 2019 through September 2021. He also previously served as part-time Chief Financial Officer of Luke Hughes and Company Limited, a private furniture manufacturer, from March 2018 through June 2019 where he oversaw a corporate restructure. Mr. Hill served as Chief Financial Officer and a member of the Board of Directors of Oxford Pharmascience Group Plc, formerly a publicly listed drug development company on AIM focused on gastro-safe NSAIDs, from October 2013 through January 2018. Mr. Hill had responsibility for the financial, legal and HR functions within the group and for AIM and other regulatory reporting. During his tenure, the company underwent a demerger, and its operations were spun out into Abaco Capital (AIM: ABAA) and private company, Oxford Pharmascience Limited. His other prior roles include serving as Group Financial Controller at Ora Capital Partners Limited, previously an AIM-listed investment vehicle, from July 2010 through October 2013, and as Audit Senior at international audit, professional services and consulting firm, Grant Thornton UK LLP, from June 2005 to June 2010. He currently serves as a director of private companies, Connexion Therapeutics Group Limited and CJH Financial Limited. Mr. Hill is a chartered accountant and holds a B.A. degree in Economics and Public Policy from Leeds Metropolitan University.